Publications by authors named "J-S Blade"

Claim this Profile
I
Is t(11;14) Always a Standard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Transplantation Trials.
David F Moreno, Albert Oriol, Javier de la Rubia, Miguel T Hernández, María Belén Iñigo

Clin Lymphoma Myeloma Leuk· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-risk features of early relapse in newly-diagnosed multiple myeloma: The impact of cytogenetics and response to initial therapy.
Andrea Manubens, Bruno Paiva, Norma C Gutiérrez, Manuela Fernandez, Maria-José Calasanz

Hemasphere· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prefusion stabilization of the Hendra and Langya virus F proteins.
Patrick O Byrne, Elizabeth G Blade, Brian E Fisher, David R Ambrozak, Ajit R Ramamohan

J Virol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma.
Irena Misiewicz-Krzeminska, Cristina de Ramón, Luis A Corchete, Patryk Krzeminski, Elizabeta A Rojas

Blood Adv· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple myeloma and SARS-CoV-2 infection: clinical characteristics and prognostic factors of inpatient mortality.
Joaquín Martínez-López, María-Victoria Mateos, Cristina Encinas, Anna Sureda, José Ángel Hernández-Rivas

Blood Cancer J· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.
Meletios A Dimopoulos, Andrzej J Jakubowiak, Philip L McCarthy, Robert Z Orlowski, Michel Attal

Blood Cancer J· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.
Ajai Chari, Joaquín Martinez-Lopez, María-Victoria Mateos, Joan Bladé, Lotfi Benboubker

Blood· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis